{"id":570827,"date":"2021-10-25T13:18:01","date_gmt":"2021-10-25T13:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=570827"},"modified":"2021-10-25T13:18:01","modified_gmt":"2021-10-25T13:18:01","slug":"cluster-headache-market-insight-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cluster-headache-market-insight-epidemiology-and-market-forecast-2030_570827.html","title":{"rendered":"Cluster Headache Market Insight, Epidemiology and Market Forecast 2030"},"content":{"rendered":"
\n
\"Cluster<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Cluster Headache Market\u2019 report deliver an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of Cluster Headache in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/div>\n

Cluster Headache Market<\/strong><\/p>\n

The Cluster Headache market report <\/a>provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Cluster Headache symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Cluster Headache symptoms treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.<\/p>\n

Cluster Headache Market Outlook<\/strong><\/p>\n

The Cluster Headache market outlook <\/a>helps build a detailed comprehension of the historical, current, and forecasted Cluster Headache market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n

This segment gives a thorough detail of Cluster Headache market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n

According to DelveInsight, the Cluster Headache market in 7MM is expected to grow in the study period 2018–2030.<\/p>\n

As per DelveInsight’s analysis, the number of patients suffering from the episodic form is much higher than those suffering from the chronic form. In the US, in 2018, there were 157,040 cases of the episodic form of CH and 39,260 cases of the chronic form of CH. These are projected to increase to 170,448 and 42,612 cases for episodic and chronic form, respectively. The treatment for cluster headache can be divided into three treatment phases: a fast-acting abortive treatment, preventive drugs, and transitional treatment to bridge the period between patients starting preventive drug dosages and the drugs asserting an effect. The acute treatment includes Triptans, High-flow oxygen, Somatostatin, and Somatostatin Analogues, among others. Prophylactic treatment drugs of the first choice are verapamil, lithium, and topiramate.<\/p>\n

Key Findings<\/p>\n

This section includes a glimpse of the Cluster Headache market in the 7MM.<\/p>\n

The market size of Cluster Headache in the seven major markets was USD 741.8 million in 2020.<\/p>\n

Cluster Headache Pipeline Development Activities<\/strong><\/p>\n

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Cluster Headache’s key players involved in developing targeted therapeutics.<\/p>\n

Major players include Lundbeck Seattle BioPharmaceuticals and Winston Laboratories.<\/p>\n

Request for sample pages @ Cluster Headache market<\/a> <\/p>\n

Table of contents<\/p>\n

1. Key Insights<\/p>\n

2. Report Introduction<\/p>\n

3. Cluster Headache Market Overview at a Glance<\/p>\n

3.1. Market Share (%) Distribution of Cluster Headache in 2018<\/p>\n

3.2. Market Share (%) Distribution of Cluster Headache in 2030<\/p>\n

4. Executive Summary of Cluster Headache<\/p>\n

5. Disease Background and Overview<\/p>\n

5.1. Introduction<\/p>\n

5.2. Classification of Cluster Headache<\/p>\n

5.3. Clinical Characteristics<\/p>\n

5.4. Comorbidities associated with Cluster Headache<\/p>\n

5.5. Cluster Headache versus Migraine<\/p>\n

5.6. Risk Factors associated with Cluster Headache<\/p>\n

5.7. Pathophysiology<\/p>\n

5.7.1. Trigeminovascular System<\/p>\n

5.7.2. Parasympathetic Activation<\/p>\n

5.7.3. Hypothalamus Activation<\/p>\n

5.8. Diagnosis<\/p>\n

5.8.1. Differential Diagnosis<\/p>\n

5.9. Treatment<\/p>\n

6. Epidemiology and Patient Population<\/p>\n

6.1. Key Findings<\/p>\n

6.2. 7MM Total Diagnosed Incident Population of Cluster Headache<\/p>\n

6.3. Epidemiology of Cluster Headache<\/p>\n

6.4. The United States<\/p>\n

6.4.1. Prevalence of Cluster Headache in the United States<\/p>\n

6.4.2. Diagnosed cases of Cluster Headache in the United States<\/p>\n

6.4.3. Type-specific cases of Cluster Headache in the United States<\/p>\n

6.4.4. Gender-specific cases of Cluster Headache in the United States<\/p>\n

6.4.5. Age-specific cases of Cluster Headache in the United States<\/p>\n

6.5. EU5<\/p>\n

6.5.1. Germany<\/p>\n

6.5.1.1. Prevalence of Cluster Headache in Germany<\/p>\n

6.5.1.2. Diagnosed cases of Cluster Headache in Germany<\/p>\n

6.5.1.3. Type-specific cases of Cluster Headache in Germany<\/p>\n

6.5.1.4. Gender-specific cases of Cluster Headache in Germany<\/p>\n

6.5.1.5. Age-specific cases of Cluster Headache in Germany<\/p>\n

6.5.2. France<\/p>\n

6.5.2.1. Prevalence of Cluster Headache in France<\/p>\n

6.5.2.2. Diagnosed cases of Cluster Headache in France<\/p>\n

6.5.2.3. Type-specific cases of Cluster Headache in France<\/p>\n

6.5.2.4. Gender-specific cases of Cluster Headache in France<\/p>\n

6.5.2.5. Age-specific cases of Cluster Headache in France<\/p>\n

6.5.3. Italy<\/p>\n

6.5.3.1. Prevalence of Cluster Headache in Italy<\/p>\n

6.5.3.2. Diagnosed cases of Cluster Headache in Italy<\/p>\n

6.5.3.3. Type-specific cases of Cluster Headache in Italy<\/p>\n

6.5.3.4. Gender-specific cases of Cluster Headache in Italy<\/p>\n

6.5.3.5. Age-specific cases of Cluster Headache in Italy<\/p>\n

6.5.4. Spain<\/p>\n

6.5.4.1. Prevalence of Cluster Headache in Spain<\/p>\n

6.5.4.2. Diagnosed cases of Cluster Headache in Spain<\/p>\n

6.5.4.3. Type-specific cases of Cluster Headache in Spain<\/p>\n

6.5.4.4. Gender-specific cases of Cluster Headache in Spain<\/p>\n

6.5.4.5. Age-specific cases of Cluster Headache in Spain<\/p>\n

6.5.5. United Kingdom<\/p>\n

6.5.5.1. Prevalence of Cluster Headache in the United Kingdom<\/p>\n

6.5.5.2. Diagnosed cases of Cluster Headache in the United Kingdom<\/p>\n

6.5.5.3. Type-specific cases of Cluster Headache in the United Kingdom<\/p>\n

6.5.5.4. Gender-specific cases of Cluster Headache in the United Kingdom<\/p>\n

6.5.5.5. Age-specific cases of Cluster Headache in the United Kingdom<\/p>\n

6.6. Japan<\/p>\n

6.6.1. Prevalence of Cluster Headache in Japan<\/p>\n

6.6.2. Diagnosed cases of Cluster Headache in Japan<\/p>\n

6.6.3. Type-specific cases of Cluster Headache in Japan<\/p>\n

6.6.4. Gender-specific cases of Cluster Headache in Japan<\/p>\n

6.6.5. Age-specific Cases of Cluster Headache in Japan<\/p>\n

7. Organizations contributing towards Cluster Headache<\/p>\n

8. Patient Journey<\/p>\n

9. Case Reports<\/p>\n

10 Marketed Products<\/p>\n

10.1. EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company<\/p>\n

10.1.1. Product Description<\/p>\n

10.1.2. Mechanism of action<\/p>\n

10.1.3. Regulatory Milestones<\/p>\n

10.1.4. Safety and Efficacy of EMGALITY<\/p>\n

10.1.5. Product Profile<\/p>\n

11. Emerging Therapies<\/p>\n

11.1. Key Cross Competition<\/p>\n

11.2. VYEPTI (Eptinezumab): Lundbeck Seattle BioPharmaceutical<\/p>\n

11.2.1. Drug Description<\/p>\n

11.2.2. Regulatory Milestones<\/p>\n

11.2.3. Clinical Development<\/p>\n

11.2.4. Clinical Trials Information<\/p>\n

11.2.5. Safety and Efficacy<\/p>\n

11.2.6. Product Profile<\/p>\n

11.3. Civamide (Zucapsaicin): Winston Laboratories<\/p>\n

11.3.1. Drug Description<\/p>\n

11.3.2. Regulatory Milestones<\/p>\n

11.3.3. Clinical Development<\/p>\n

11.3.4. Clinical Trials Information<\/p>\n

11.3.5. Safety and Efficacy<\/p>\n

11.3.6. Product Profile<\/p>\n

12. Other Drugs under Development<\/p>\n

12.1. Zolmitriptan transdermal (C213): Zosano Pharma<\/p>\n

12.1.1. Drug Description<\/p>\n

12.1.2. Clinical Development<\/p>\n

12.1.3. Clinical Trials Information<\/p>\n

12.1.4. Product Profile<\/p>\n

13. Cluster Headache: Seven Major Market Analysis<\/p>\n

13.1. Key Findings<\/p>\n

13.2. Market Size of Cluster Headache in 7MM<\/p>\n

13.3. Market Outlook<\/p>\n

13.4. United States Market Size<\/p>\n

13.1.1. Total Market Size of Cluster Headache in the United States<\/p>\n

13.1.2. Market Size of Cluster Headache by Therapies in the United States<\/p>\n

13.5. EU-5 Market Size<\/p>\n

13.5.1. Germany<\/p>\n

13.5.1.1. Total Market Size of Cluster Headache in Germany<\/p>\n

13.5.1.2. Market Size of Cluster Headache by Therapies in Germany<\/p>\n

13.5.2. France<\/p>\n

13.5.2.1. Total Market Size of Cluster Headache in France<\/p>\n

13.5.2.2. Market Size of Cluster Headache by Therapies in France<\/p>\n

13.5.3. Italy<\/p>\n

13.5.3.1. Total Market Size of Cluster Headache in Italy<\/p>\n

13.5.3.2. Market Size of Cluster Headache by Therapies in Italy<\/p>\n

13.5.4. Spain<\/p>\n

13.5.4.1. Total Market Size of Cluster Headache in Spain<\/p>\n

13.5.4.2. Market Size of Cluster Headache by Therapies in Spain<\/p>\n

13.5.5. United Kingdom<\/p>\n

13.5.5.1. Total Market Size of Cluster Headache in the United Kingdom<\/p>\n

13.5.5.2. Market Size of Cluster Headache by Therapies in the United Kingdom<\/p>\n

13.6. Japan<\/p>\n

13.6.1. Total Market size of Cluster Headache in Japan<\/p>\n

13.6.2. Market Size of Cluster Headache by Therapies in Japan<\/p>\n

14. KOL Views<\/p>\n

15. Market Drivers<\/p>\n

16. Market Barriers<\/p>\n

17. SWOT Analysis<\/p>\n

18. Unmet Needs<\/p>\n

19. Market Access<\/p>\n

20. Appendix<\/p>\n

20.1. Bibliography<\/p>\n

20.2. Report Methodology<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About DelveInsight<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Cluster Headache Market\u2019 report deliver an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of Cluster Headache in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-570827","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/570827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=570827"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/570827\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=570827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=570827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=570827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}